Cargando…
S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428272/ http://dx.doi.org/10.1097/01.HS9.0000967488.92046.ec |
| _version_ | 1785090428240920576 |
|---|---|
| author | Urban, Aleksandra Hermansen, Johanne Yin, Yanping Kong, Weikaixin Teglgaard, Rebecca Brieghel, Christian Kersting, Sabina Tjønnfjord, Geir E. Levin, Mark-David Tran, Hoa T. T. Mattsson, Mattias Ranti, Juha Veldhuis, Gerrit-Jan Da Cunha-Bang, Caspar Mous, Rogier Dubois, Julie Kater, Arnon Niemann, Carsten Aittokallio, Tero Skånland, Sigrid |
| author_facet | Urban, Aleksandra Hermansen, Johanne Yin, Yanping Kong, Weikaixin Teglgaard, Rebecca Brieghel, Christian Kersting, Sabina Tjønnfjord, Geir E. Levin, Mark-David Tran, Hoa T. T. Mattsson, Mattias Ranti, Juha Veldhuis, Gerrit-Jan Da Cunha-Bang, Caspar Mous, Rogier Dubois, Julie Kater, Arnon Niemann, Carsten Aittokallio, Tero Skånland, Sigrid |
| author_sort | Urban, Aleksandra |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10428272 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104282722023-08-17 S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL Urban, Aleksandra Hermansen, Johanne Yin, Yanping Kong, Weikaixin Teglgaard, Rebecca Brieghel, Christian Kersting, Sabina Tjønnfjord, Geir E. Levin, Mark-David Tran, Hoa T. T. Mattsson, Mattias Ranti, Juha Veldhuis, Gerrit-Jan Da Cunha-Bang, Caspar Mous, Rogier Dubois, Julie Kater, Arnon Niemann, Carsten Aittokallio, Tero Skånland, Sigrid Hemasphere Oral Sessions Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428272/ http://dx.doi.org/10.1097/01.HS9.0000967488.92046.ec Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Oral Sessions Urban, Aleksandra Hermansen, Johanne Yin, Yanping Kong, Weikaixin Teglgaard, Rebecca Brieghel, Christian Kersting, Sabina Tjønnfjord, Geir E. Levin, Mark-David Tran, Hoa T. T. Mattsson, Mattias Ranti, Juha Veldhuis, Gerrit-Jan Da Cunha-Bang, Caspar Mous, Rogier Dubois, Julie Kater, Arnon Niemann, Carsten Aittokallio, Tero Skånland, Sigrid S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title | S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title_full | S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title_fullStr | S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title_full_unstemmed | S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title_short | S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL |
| title_sort | s144: btk and bcl-2 activity at baseline predicts mrd status for chronic lymphocytic leukemia patients treated with ibrutinib + venetoclax in the hovon 141/vision trial |
| topic | Oral Sessions |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428272/ http://dx.doi.org/10.1097/01.HS9.0000967488.92046.ec |
| work_keys_str_mv | AT urbanaleksandra s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT hermansenjohanne s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT yinyanping s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT kongweikaixin s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT teglgaardrebecca s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT brieghelchristian s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT kerstingsabina s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT tjønnfjordgeire s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT levinmarkdavid s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT tranhoatt s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT mattssonmattias s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT rantijuha s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT veldhuisgerritjan s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT dacunhabangcaspar s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT mousrogier s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT duboisjulie s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT katerarnon s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT niemanncarsten s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT aittokalliotero s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial AT skanlandsigrid s144btkandbcl2activityatbaselinepredictsmrdstatusforchroniclymphocyticleukemiapatientstreatedwithibrutinibvenetoclaxinthehovon141visiontrial |